People
BigHat is a Bay-area startup that’s reimagining antibody development with the help of AI and ML (machine learning) technologies through data-driven discovery.
Anat Ashkenazi was tapped to take over as chief financial officer of Eli Lilly following the abrupt resignation of Josh Smiley, who departed the company following allegations of an inappropriate relationship with an employee.
He will be replaced on an interim-basis by Thomas McCourt, who currently serves as company president.
James C. Mullen succeeds Cynthia Collins as Editas’ CEO, effective on February 15, 2021.
A Portland, Oregon biotech consultant is facing two counts of insider trading charges, with federal prosecutors and securities regulators claiming the defendant made profitable stock trades using confidential information he learned during his time consulting for Abeona Therapeutics.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Merck Chief Executive Officer Kenneth C. Frazier is stepping down from his role atop the helm of the pharma giant on June 30 after nearly 30 years with the company.
The next several years will be transformative in the cell and gene therapy space, and Immatics’ Chief Medical Officer Cedrik M. Britten believes his company’s engineered T-cell receptors may play an important role in providing treatment options for cancer patients.
MOMA Therapeutics and Eli Lilly are both experiencing significant changes in their leadership roster, with one Takeda alum taking the helm at MOMA and an R&D chief at Lilly shooting toward the exit door.
Medical community struggles over how to help patients with long-lasting, serious side effects even after “recovering” from COVID-19 infection.
PRESS RELEASES